Zealand Pharma wins positive CHMP opinion for Zeydovio in short bowel syndrome
CHMP issued a positive opinion recommending EU marketing authorization for Zeydovio (glepaglutide) for adults with short bowel syndrome; European Commission decision expected in ~67 days.